Plasmocin prot

Plasmocin™
For treatment and prevention of Mycoplasma contamination of cel culture PRODUCT INFORMATION
In contrast to most anti-Mycoplasma compounds that act solely in Content:
vitro, Plasmocin™ is active on Mycoplasma present in cel culture
Plasmocin™ is supplied as 1 ml tubes containing a sterile, yel ow
medium, and on intracel ular Mycoplasma found in some specialized mammalian cells. The two antibiotics comprising Plasmocin™ are
- ant-mpt: 2x 1ml at 25mg/ml (50mg). For elimination of
actively transported into mammalian cel s providing a synergistic killing effect on intracellular Mycoplasma without any apparent - ant-mpp: 5x 2ml at 2.5mg/ml (25mg). For prevention of
adverse effect on cellular metabolism. This benefit insures that after being treated with Plasmocin™, a cel culture is not reinfected by
Shipping and Storage:
Mycoplasma released from the intracellular compartments of Plasmocin™ is shipped at room temperature. Upon receipt, it should
infected cells following antibiotic removal. At high concentrations be stored at 4°C for immediate use and is stable at this temperature for of Plasmocin™, slowdown of cel growth rate may be observed.
several weeks. If Plasmocin™ is not to be used immediately, then
This slowing down is mainly due to the inhibition of mitochondria freeze at -20°C for long term storage.
respiration by Plasmocin™. However when Plasmocin™ is removed
Plasmocin™ is stable for at least two years when stored at -20°C.
from culture medium, cells return rapidly to their normal growth Note: Presence of crystals does not alter properties of the product.
rate. The anti-Mycoplasma activity of Plasmocin™ is unaltered in
Vortex the tube until the crystals disappear. cell culture medium containing up to 20% serum.
Quality Control:
Activity of Plasmocin™ is rigorously control ed by physicochemical
RESISTANCE TO PLASMOCIN™
In repeated experiments aimed to determine the mutation rate of Mycoplasma hominis, Mycoplasma bovis and Acholeplasma vituli to GENERAL PRODUCT USE
Plasmocin™, no resistance in liquid cultures has ever been identified,
Plasmocin™ is used to cure cel lines infected by Mycoplasma and
indicating a possible mutation rate lower than 10-9. Therefore, related cel wal -less bacteria. Plasmocin™ can also be used as a routine
development of resistant Mycoplasma strains is highly unlikely.
addition in liquid media to prevent Mycoplasma and more general y bacterial contamination in smal and large animal cel cultures.
Treatment of Mycoplasma Infected Cel Cultures:
BACKGROUND
Plasmocin™ treatment (ant-mpt) requires lit le hands-on manipulation
Recent reports estimate Mycoplasma contamination in up to 63% of and is completed in only two weeks. Typical y, Plasmocin™ is used at
al cel cultures. Mycoplasma cannot be detected by visual inspection 25 µg/ml which represents a 1:1000 dilution of the 25 mg/ml stock solution.
and may not noticeably affect cel culture growth rates. However, Working concentration of Plasmocin™ ranges from 12.5 to 37.5 µg/ml.
Mycoplasma infection has been shown to alter DNA, RNA and protein synthesis, introduce chromosomal aberrations and cause alterations or 1- Split an actively dividing culture of cel s into medium containing modifications of host cel plasma membrane antigens.
12-25µg/ml of Plasmocin™.
Plasmocin
2- Remove and replace with fresh Plasmocin™ containing medium
™ is a new generation of bactericidal antibiotic preparation
stronglyactiveonMycoplasmainfectedcel s.Itisactiveatlowconcentrations on a broad range of gram positive and gram negative bacteria otherwise 3. For maintenance of a Mycoplasma free culture, continue the use of resistant to the mixture of streptomycin and penicil in antibiotics Plasmocin™ at a concentration of 5µg/ml.
Note: If Mycoplasma elimination is not completed after a two week
treatment, you may continue the treatment for an additional week DESCRIPTION / PROPERTIES
and/or increase the concentration to 37.5 µg/ml. Plasmocin™ contains two newly developed bactericidal components:
Maintenance or prophylactic use against Mycoplasma infections:
one acts on the protein synthesis machinery by interfering with To prevent Mycoplasma and related cell wall-less bacteria ribosome translation, and the other acts on DNA replication by contaminations of cell cultures that have been previously tested interfering with the replication fork. These two specific and separate to be contamination-free, use Plasmocin™ prevention (ant-mpp)
targets are found only in Mycoplasma and many other bacteria, at a concentration of 5 µg/ml that represents a 1:500 dilution of the and are completely absent in eukaryotic cells.
TECHNICAL SUPPORTToll free (US): 888-457-5873Outside US: (+1) 858-457-5873Europe: +33 562-71-69-39E-mail: info@invivogen.com

Source: http://www.shdsyy.com.cn/web/themes/165/userfiles/download/2013/3/15/rroteghcoxvby3l.pdf